Surendera Tyagi
Corporate Officer/Principal chez Association for Accessible Medicines
Profil
Surendera Tyagi is a Member at the Association for Accessible Medicines.
Previously, he was the Chief Scientific Officer and Global Head-R&D at Hikma Pharmaceuticals Plc from 2018 to 2019.
He was also the Vice President of the Oncology Business Unit at Fresenius Kabi Pharmaceuticals Holding LLC from 2009 to 2011.
In 2008, he was the Chief Scientific Officer at Fresenius Kabi Oncology Ltd.
Dr. Tyagi received his undergraduate degree from Purdue University and his doctorate from the University of Oklahoma.
Postes actifs de Surendera Tyagi
Sociétés | Poste | Début |
---|---|---|
Association for Accessible Medicines
Association for Accessible Medicines Miscellaneous Commercial ServicesCommercial Services The Association for Accessible Medicines is an organization that aims to make generic and biosimilar medicines more accessible to those who need them. The organization is based in Arlington, VA. The non-profit company believes that increasing competition is the key to tackling the high cost of prescription drugs, rather than shifting costs among healthcare stakeholders. In 2022, generic and biosimilar prescription medicines saved $408 billion for the healthcare system overall, with more than $2.90 trillion saved over the past 10 years. The company was founded by Milan Puskar, Robert R. Grusky. David Gaugh has been the CEO of the company since 2012. | Corporate Officer/Principal | - |
Anciens postes connus de Surendera Tyagi
Sociétés | Poste | Fin |
---|---|---|
HIKMA PHARMACEUTICALS PLC | Chief Tech/Sci/R&D Officer | 01/02/2019 |
FRESENIUS KABI ONCOLOGY LTD | Chief Tech/Sci/R&D Officer | 01/12/2008 |
Fresenius Kabi Pharmaceuticals Holding LLC
Fresenius Kabi Pharmaceuticals Holding LLC Pharmaceuticals: MajorHealth Technology Fresenius Kabi Pharmaceuticals Holding LLC is a pharmaceutical company, which engages in the development, manufacturing, and marketing of injectable pharmaceutical products. It primarily focuses on the injectable oncology, anti-infective, anesthetic/analgesic, and critical care markets. The firm manufactures products in each of the three basic forms, which include liquid, powder, and lyophilized or freeze-dried. Its products are generally used in hospitals, long-term care facilities, alternate care sites and clinics. The company was founded on July 2, 2008 and is headquartered in Wilmington, DE. | Corporate Officer/Principal | - |
Formation de Surendera Tyagi
Purdue University | Undergraduate Degree |
University of Oklahoma | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
HIKMA PHARMACEUTICALS PLC | Health Technology |
Entreprise privées | 3 |
---|---|
Fresenius Kabi Pharmaceuticals Holding LLC
Fresenius Kabi Pharmaceuticals Holding LLC Pharmaceuticals: MajorHealth Technology Fresenius Kabi Pharmaceuticals Holding LLC is a pharmaceutical company, which engages in the development, manufacturing, and marketing of injectable pharmaceutical products. It primarily focuses on the injectable oncology, anti-infective, anesthetic/analgesic, and critical care markets. The firm manufactures products in each of the three basic forms, which include liquid, powder, and lyophilized or freeze-dried. Its products are generally used in hospitals, long-term care facilities, alternate care sites and clinics. The company was founded on July 2, 2008 and is headquartered in Wilmington, DE. | Health Technology |
Association for Accessible Medicines
Association for Accessible Medicines Miscellaneous Commercial ServicesCommercial Services The Association for Accessible Medicines is an organization that aims to make generic and biosimilar medicines more accessible to those who need them. The organization is based in Arlington, VA. The non-profit company believes that increasing competition is the key to tackling the high cost of prescription drugs, rather than shifting costs among healthcare stakeholders. In 2022, generic and biosimilar prescription medicines saved $408 billion for the healthcare system overall, with more than $2.90 trillion saved over the past 10 years. The company was founded by Milan Puskar, Robert R. Grusky. David Gaugh has been the CEO of the company since 2012. | Commercial Services |
Fresenius Kabi Oncology Ltd.
Fresenius Kabi Oncology Ltd. Miscellaneous Commercial ServicesCommercial Services Fresenius Kabi Oncology Ltd. is a research and development company, which engages in manufacturing and development of oncology drugs. It also develops active pharmaceutical ingredients, intermediates and oral and injectable finished dosage forms. The company was founded on March 18, 2003 and is headquartered in Gurgaon, India. | Commercial Services |